Journal
JOURNAL OF SURGICAL ONCOLOGY
Volume 109, Issue 4, Pages 314-319Publisher
WILEY-BLACKWELL
DOI: 10.1002/jso.23554
Keywords
melanoma; intralesional therapy; treatment
Ask authors/readers for more resources
Rose Bengal is a novel injectable agent that has been evaluated as a rational treatment strategy for melanoma patients with recurrent unresectable local/regional metastases accessible for intralesional injection. PV-10 (10% Rose Bengal) has completed phase 1 and phase 2 multi-center clinical trials demonstrating significant local/regional disease control and also responses in non-injected regional bystander lesions and distant metastases. The published results of studies that have assessed PV-10 are presented, and the rationale for combining its use with recently approved immunotherapeutic agents is discussed. J. Surg. Oncol. 2014 109:314-319. (c) 2014 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available